Key facts
- This page summarizes Amar Murugan's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 18:27.
Amar Murugan - 16 Aug 2024 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Reporting relationship
- EVP, Chief Legal Officer
- Issuer ticker
- ATRA
- Reported as of
- 16 Aug 2024
- Net transaction value
- -$7,677
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 18:27:26 UTC
- Prior SEC filing
- 20 May 2024
- Next SEC filing
- 22 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Chao, Attorney-in-Fact for Amar Murugan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amar Murugan filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 20 May 2024.
- Current net transaction value: -$7,677.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Sale
- Transaction value
- $5,814
- Shares
- -877
- Change %
- -3.1%
- Price
- $6.63
- Shares after
- 27,108
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
ATRA
transaction
Common Stock
Sale
- Transaction value
- $1,273
- Shares
- -192
- Change %
- -0.71%
- Price
- $6.63
- Shares after
- 26,916
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ATRA
transaction
Common Stock
Sale
- Transaction value
- $590
- Shares
- -89
- Change %
- -0.33%
- Price
- $6.63
- Shares after
- 26,827
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
Footnote F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Footnote F3
This amount includes 4,507 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.